NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Neocytolysis contributes to the anemia of renal diseaseNeocytolysis is a recently described physiological process affecting the selective hemolysis of young red blood cells in circumstances of plethora. Erythropoietin (EPO) depression appears to initiate the process, providing the rationale to investigate its contributions to the anemia of renal disease. When EPO therapy was withheld, four of five stable hemodialysis patients showed chromium 51 (51Cr)-red cell survival patterns indicative of neocytolysis; red cell survival was short in the first 9 days, then normalized. Two of these four patients received oral 13C-glycine and 15N-glycine, and there was a suggestion of pathological isotope enrichment of stool porphyrins when EPO therapy was held, again supporting selective hemolysis of newly released red cells that take up the isotope (one patient had chronic hemolysis indicated by isotope studies of blood and stool). Thus, neocytolysis can contribute to the anemia of renal disease and explain some unresolved issues about such anemia. One implication is the prediction that intravenous bolus EPO therapy is metabolically and economically inefficient compared with lower doses administered more frequently subcutaneously.
Document ID
20040142099
Acquisition Source
Legacy CDMS
Document Type
Reprint (Version printed in journal)
Authors
Rice, L.
(Methodist Hospital Houston, TX, United States)
Alfrey, C. P.
Driscoll, T.
Whitley, C. E.
Hachey, D. L.
Suki, W.
Date Acquired
August 22, 2013
Publication Date
January 1, 1999
Publication Information
Publication: American journal of kidney diseases : the official journal of the National Kidney Foundation
Volume: 33
Issue: 1
ISSN: 0272-6386
Subject Category
Life Sciences (General)
Distribution Limits
Public
Copyright
Other
Keywords
Non-NASA Center
NASA Discipline Regulatory Physiology

Available Downloads

There are no available downloads for this record.
No Preview Available